Page last updated: 2024-10-30

leflunomide and Non-alcoholic Fatty Liver Disease

leflunomide has been researched along with Non-alcoholic Fatty Liver Disease in 1 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Barbarroja, N1
Ruiz-Ponce, M1
Cuesta-López, L1
Pérez-Sánchez, C1
López-Pedrera, C1
Arias-de la Rosa, I1
Collantes-Estévez, E1

Reviews

1 review available for leflunomide and Non-alcoholic Fatty Liver Disease

ArticleYear
Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Biological Products; Cardiovascular Diseases; Heart Dis

2022